HEMATOLOGIC BIOMARKERS AS PREDICTORS OF IMMUNE-RELATED CUTANEOUS ADVERSE EVENTS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Purpose: The study aimed to evaluate the association between baseline hematologic parameters and the development of immune-related cutaneous adverse events (irCAEs) in patients treated with immune checkpoint inhibitors (ICIs). Identifying predictive biomarkers for cutaneous toxicity is essential for early risk stratifi...